Last reviewed · How we verify
Direct-acting oral anticoagulation
Direct-acting oral anticoagulants inhibit specific clotting factors (either Factor IIa or Factor Xa) to prevent thrombus formation.
Direct-acting oral anticoagulants inhibit specific clotting factors (either Factor IIa or Factor Xa) to prevent thrombus formation. Used for Atrial fibrillation for stroke prevention, Venous thromboembolism (deep vein thrombosis and pulmonary embolism) treatment and prevention, Acute coronary syndrome (in combination with antiplatelet therapy).
At a glance
| Generic name | Direct-acting oral anticoagulation |
|---|---|
| Sponsor | Hospital Universitario La Fe |
| Drug class | Direct-acting oral anticoagulant (DOAC) |
| Target | Factor IIa or Factor Xa |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
This drug class includes Factor IIa inhibitors (dabigatran) and Factor Xa inhibitors (apixaban, rivaroxaban, edoxaban), which directly block key enzymes in the coagulation cascade. By inhibiting these factors, DOACs prevent the conversion of prothrombin to thrombin or reduce Factor Xa activity, thereby reducing clot formation without requiring monitoring of INR levels like warfarin.
Approved indications
- Atrial fibrillation for stroke prevention
- Venous thromboembolism (deep vein thrombosis and pulmonary embolism) treatment and prevention
- Acute coronary syndrome (in combination with antiplatelet therapy)
Common side effects
- Bleeding (major and minor)
- Gastrointestinal bleeding
- Dyspepsia
- Nausea
- Intracranial hemorrhage
Key clinical trials
- The Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Atrial Fibrillation (PHASE4)
- The Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Venous Thromboembolism (DANNOAC-VTE) (PHASE4)
- Anticoagulation Therapy Timing in Atrial Fibrillation After Acute and Chronic Subdural Hematoma (NA)
- Periprocedural Continuation Versus Interruption of Oral Anticoagulant Drugs During Transcatheter Aortic Valve Implantation (POPular PAUSE TAVI) (PHASE4)
- Uninterrupted Direct-acting Oral Anticoagulation in Patients Undergoing Transradial Percutaneous Coronary Procedures (PHASE4)
- Efficacy and Safety of Apixaban in COVID-19 Coagulopathy Patients With Respiratory Severity Under Critical Care (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Direct-acting oral anticoagulation CI brief — competitive landscape report
- Direct-acting oral anticoagulation updates RSS · CI watch RSS
- Hospital Universitario La Fe portfolio CI